ADMA BIOLOGICS, INC. (ADMA) Gross Margin
- Gross margin · 12 months: Value 64.71%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 64.71% | Gross profit / revenue. Period ending 2026-06-30. $331.47M ÷ $512.27M × 100 ≈ 64.71% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 331.47M USD | Gross Profit |
| Revenue | 512.27M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $331.47M | $512.27M | (m) | 64.71% |
| 2026-03-31 | $312.42M | $509.86M | (m) | 61.27% |
| 2025-12-31 | $292.76M | $510.17M | (m) | 57.39% |
| 2025-09-30 | $267.28M | $488.56M | (m) | 54.71% |
| 2025-06-30 | $251.31M | $474.17M | (m) | 53.00% |
| 2025-03-31 | $241.54M | $459.38M | (m) | 52.58% |
| 2024-12-31 | $219.55M | $426.45M | (m) | 51.48% |
| 2024-09-30 | $187.31M | $382.81M | (m) | 48.93% |
| 2024-06-30 | $152.30M | $330.24M | (m) | 46.12% |
| 2024-03-31 | $111.54M | $283.18M | (m) | 39.39% |
| 2023-12-31 | $88.94M | $258.21M | (m) | 34.44% |
| 2023-09-30 | $72.03M | $234.29M | (m) | 30.74% |
| 2023-06-30 | $57.04M | $208.11M | (m) | 27.41% |
| 2023-03-31 | $48.12M | $181.89M | (m) | 26.45% |
| 2022-12-31 | $35.27M | $154.08M | (m) | 22.89% |
| 2022-09-30 | $24.60M | $130.48M | (m) | 18.85% |
| 2022-06-30 | $15.33M | $110.07M | (m) | 13.93% |
| 2022-03-31 | $6.56M | $94.00M | (m) | 6.98% |
| 2021-12-31 | $1.17M | $80.94M | (m) | 1.45% |
| 2021-09-30 | (m) | $68.52M | (m) | (m) |
| 2021-06-30 | (m) | $58.11M | (m) | (m) |
| 2021-03-31 | (m) | $48.07M | (m) | (m) |
| 2020-12-31 | (m) | $42.22M | (m) | (m) |
| 2020-09-30 | (m) | $40.30M | (m) | (m) |
| 2020-06-30 | (m) | $37.25M | (m) | (m) |
| 2020-03-31 | (m) | $36.02M | (m) | (m) |
| 2019-12-31 | (m) | $29.35M | (m) | (m) |
| 2019-09-30 | (m) | $21.37M | (m) | (m) |
| 2019-06-30 | (m) | $18.38M | (m) | (m) |
| 2019-03-31 | (m) | $16.47M | (m) | (m) |
| 2018-12-31 | $-25.21M | $16.99M | (m) | -148.42% |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-6.40M | (m) | (m) | (m) |
| 2017-09-30 | $-5.17M | (m) | (m) | (m) |
| 2017-06-30 | $2.59M | (m) | (m) | (m) |
| 2017-03-31 | $4.46M | (m) | (m) | (m) |
| 2016-12-31 | $4.30M | (m) | (m) | (m) |
| 2016-09-30 | $4.00M | (m) | (m) | (m) |
| 2016-06-30 | $3.53M | (m) | (m) | (m) |
| 2016-03-31 | $3.13M | (m) | (m) | (m) |
| 2015-12-31 | $2.87M | (m) | (m) | (m) |
| 2015-09-30 | $2.39M | (m) | (m) | (m) |
| 2015-06-30 | $2.15M | (m) | (m) | (m) |
| 2015-03-31 | $2.18M | (m) | (m) | (m) |
| 2014-12-31 | $2.17M | (m) | (m) | (m) |
| 2014-09-30 | $1.78M | (m) | (m) | (m) |
| 2014-06-30 | $1.67M | (m) | (m) | (m) |
| 2014-03-31 | $1.36M | (m) | (m) | (m) |
| 2013-12-31 | $1.04M | (m) | (m) | (m) |
| 2013-09-30 | $1.05M | $3.17M | (m) | 33.01% |
| 2013-06-30 | $880.03K | $2.42M | (m) | 36.37% |
| 2013-03-31 | $710.75K | $1.91M | (m) | 37.28% |
| 2012-12-31 | $449.06K | $1.12M | (m) | 40.16% |
| 2012-09-30 | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | $553.47K | $761.04K | (m) | 72.73% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |